Investigate how microglial senescence drives ALS progression through inflammation, trophic support loss, and protein aggregation. Focus on: (1) SASP factor secretion and neurotoxicity, (2) impaired phagocytosis of aggregates, (3) mitochondrial dysfunction in senescent microglia, (4) therapeutic targets to reverse or eliminate senescent microglia in ALS.
TBK1 deficiency in microglia creates a pathological cascade that directly generates ALS-driving TDP-43 pathology through senescence-associated secretory phenotype (SASP) mechanisms. When TBK1 is lost or mutated, microglia become locked in a senescent state characterized by dysregulated NF-κB and IRF3 signaling, defective p62-mediated autophagy, and chronic cGAS-STING pathway activation. This senescent microglial state produces a toxic SASP cocktail enriched in matrix metalloproteinase-9 (MMP-9), which is secreted into the extracellular space and taken up by neighboring neurons. Once internalized, MMP-9 acts as a pathological protease that cleaves full-length TDP-43 protein at specific C-terminal sites, generating neurotoxic 25kDa and 35kDa fragments.
...
TBK1 deficiency in microglia creates a pathological cascade that directly generates ALS-driving TDP-43 pathology through senescence-associated secretory phenotype (SASP) mechanisms. When TBK1 is lost or mutated, microglia become locked in a senescent state characterized by dysregulated NF-κB and IRF3 signaling, defective p62-mediated autophagy, and chronic cGAS-STING pathway activation. This senescent microglial state produces a toxic SASP cocktail enriched in matrix metalloproteinase-9 (MMP-9), which is secreted into the extracellular space and taken up by neighboring neurons. Once internalized, MMP-9 acts as a pathological protease that cleaves full-length TDP-43 protein at specific C-terminal sites, generating neurotoxic 25kDa and 35kDa fragments. These aberrant TDP-43 fragments cannot properly shuttle between nucleus and cytoplasm, instead accumulating in cytoplasmic inclusions that serve as pathological seeds for further TDP-43 aggregation. The fragmented TDP-43 species exhibit enhanced prion-like properties, propagating from cell to cell and recruiting normal TDP-43 into insoluble aggregates. This creates a self-amplifying cycle where TBK1-deficient senescent microglia continuously secrete MMP-9, generating more pathological TDP-43 fragments that spread throughout neural networks. The mechanism explains how TBK1 mutations cause ALS through a non-cell-autonomous pathway: the primary defect occurs in microglia, but the pathological consequence manifests as neuronal TDP-43 proteinopathy. This hypothesis predicts that MMP-9 inhibition or senolytic therapies targeting senescent microglia could interrupt the TBK1→MMP-9→TDP-43 fragmentation axis.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["dsDNA/dsRNA or Bacteria STING/MAVS Signal"]
B["TBK1 Activation IKK-epsilon Complex"]
C["IRF3 Phosphorylation Ser396 by TBK1"]
D["IRF3 Dimerization Nuclear Import"]
E["Type-I IFN Expression IFN-beta/IFN-alpha"]
F["Antiviral Defense ISG Upregulation"]
G["TBK1 Loss-of-Function ALS10 Mutations"]
H["OPTN/p62 Phosphorylation Selective Autophagy"]
A --> B
B --> C
B --> H
C --> D
D --> E
E --> F
G -.->|"impairs"| B
G -.->|"impairs"| H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for TBK1 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
Manganelli F et al., Cells 2026 Mar 6 · PMID:41827910
No claimMODERATE
Smeyers J et al., Cell Rep 2025 Nov 25 · PMID:41171761
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Scientific Skeptic Assessment: TBK1 Loss/Microglial Senescence Hypothesis in ALS
Executive Summary
The hypothesis proposes a coherent and mechanistically plausible model linking TBK1 loss-of-function mutations to ALS pathogenesis through microglial senescence and SASP. While supported by compelling animal model data and consistent with known roles for TBK1 in inflammatory signaling, this framework faces significant challenges from the prevailing evidence suggesting neuronal autophagy dysfunction as the primary TBK1-dependent pathogenic mechanism. I identify critical gaps in causal evi
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Scientific Synthesis: TBK1 Loss/Microglial Senescence Hypothesis in ALS
Integration of Prior Arguments
The Core Tension
The debate crystallizes around a fundamental question: Is the primary TBK1 pathogenic axis neuronal (autophagy/proteostasis) or microglial (senescence/SASP)?
The Theorist presents compelling circumstantial evidence: microglia-specific TBK1 deletion reproduces aged transcriptional signatures, RIPK1-driven inflammation emerges from TBK1 insufficiency, and cGAS-STING activation downstream provides mechanistic plausibility. The Skeptic counters with pho
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.